This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Novartis moves to dismiss Walmart's US antitrust claims over generic drugs

( March 2, 2026, 23:37 GMT | Official Statement) -- MLex Summary: Novartis AG has moved to dismiss Walmart's first amended US antitrust claims over generic drugs, arguing that Walmart does not establish personal jurisdiction over Novartis, and its attempt to impute Sandoz Inc.'s domestic contacts to Novartis AG through so-called "alter ego" jurisdiction also fails. Besides this fatal defect, Walmart also fails to allege "even a single text message, email, or other communication attributable to Novartis AG indicative of any agreement," the motion to dismiss filed in the Eastern District of Pennsylvania said. Lastly, Walmart's claims are long out of time, and the 16-year-old allegations cannot survive under the Sherman Act's four-year statute of limitations, Novartis said.See attached file....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections